Showing 1-10 of 19 results for "".
- Emmanuel Caeymaexhttps://practicaldermatology.com/profiles/emmanuel-caeymaex/LAabQl/
- EMA to Review UCB’s Bimekizumab for HShttps://practicaldermatology.com/news/ema-to-review-ucbs-bimekizumab-for-hs/2461869/The European Medicines Agency (EMA) will reviww UCB’s marketing authorization application for bimekizumab for the treatment of adults with moderate to severe hidradenitis suppurativa (HS). Bimekizumab is an IL-17A and IL-17F inhibitor. The safety and efficacy of bimekizumab in HS have not been est…
- EMA Accepts Marketing Authorization Applications for UCB's Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritishttps://practicaldermatology.com/news/ema-accepts-marketing-authorization-applications-for-ucbs-bimekizumab-in-psoriatic-arthritis-and-axial-spondyloarthritis/2461354/The European Medicines Agency (EMA) has accepted for regulatory review the two marketing authorization applications for UCB's bimekizumab for the treatment of adult patients with active psoriatic arthritis (PsA), and adult patients with active axial spondyloarthritis (axSpA). “These two regulatory…
- UCB, Stanford Medicine Partner to Seek New Ways to Treat HS, Other Diseaseshttps://practicaldermatology.com/news/ucb-stanford-medical-partner-to-seek-new-ways-to-treat-hs-other-diseases/2460613/UCB and Stanford Medicine are joining forces for a multi-year collaboration to develop unique solutions that combine clinical, real-world, omics, and other data sets — along with the required expertise — to identify which patients will respond best and ultimately, deliver better patient outcomes. …
- FDA Accepts BLA for Bimekizumab for Plaque Psoriasishttps://practicaldermatology.com/news/fda-accepts-bla-for-bimekizumab-for-plaque-psoriasis/2460536/The FDA and the European Medicines Agency (EMA) have accepted the Biologics License Application (BLA) and Marketing Authorization Application (MAA), respectively, for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis. “After a series of positive Phase 3 data readouts…
- Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/long-term-complete-skin-clearance-data-for-bimekizumab-in-moderate-to-severe-plaque-psoriasis/2461137/UCB presented 11 abstracts on bimekizumab in the treatment of adults with moderate to severe plaque psoriasis at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Boston, MA, including a late breaking oral platform presentation and 10 posters. The platform presentation details new an…
- Bimekizumab Bests Cosentyx in Achieving Complete Psoriasis Skin Clearancehttps://practicaldermatology.com/news/bimekizumab-bests-cosentyx-in-achieving-complete-psoriasis-skin-clearance/2460478/UCB’s investigational IL-17A and IL-17F inhibitor bimekizumab outperformed the IL-17A inhibitor Cosentyx (secukinumab) in a head-to-head Phase 3 b study of adult patients with moderate-to-severe plaque psoriasis. This is the first head-to-head study comparing anti-IL-17 treatments, and the first t…
- Bimekizumab Provides Long-Term Skin Clearance for Psoriasis Patients in Phase 2b Studyhttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-extension-study/2459873/UCB’s bimekizumab demonstrated long-term maintenance of complete or almost complete skin disease resolution for psoriasis patients, according to results from the Phase 2b BE ABLE 2 Extension Study presented at the 2019 American Academy of Dermatology Annual Meeting (AAD) in Washington, DC. An inves…
- UCB: Study Data for Cimzia and Bimekizumab Presented at EADVhttps://practicaldermatology.com/news/ucb-data-for-cimzia-and-at-eadv/2457606/UCB has presented new findings on Cimzia® (certolizumab pegol) and one of its key pipeline molecules, bimekizumab, for the treatment of moderate-to-severe chronic plaque psoriasis (PSO), along with findings from an international survey on physicians’ perceptions about treating women with chronic in…
- UCB's Bimekizumab Performs Well in Hidradenitis Suppurativahttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-hidradenitis-suppurativa/2461464/UCB’s bimekizumab may be a promising treatment approach in adults with moderate to severe hidradenitis suppurativa, according to topline results from two Phase 3 studies, BE HEARD I and BE HEARD II. The positive results from these two studies will form the basis of global regulatory license applic…
- Prev
- Next